For the quarter ending 2026-03-31, ARTV had -$5,746K decrease in cash & cash equivalents over the period. -$21,192K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Operating expenses | - | 89,810 | - | - |
| Other income, net | - | 5,945 | - | - |
| Net loss | -23,516 | -20,772 | -21,528 | -41,565 |
| Depreciation and amortization | 666 | 666 | 662 | 1,269 |
| Stock-based compensation | 1,593 | 1,589 | 1,631 | 3,601 |
| Change in fair value of safes (including related party amounts of 0 and 2,911, respectively) | - | 0 | - | - |
| Accretion of discounts and amortization of premiums on investments, net | 199 | 291 | 357 | 1,232 |
| Accounts receivable (including related party amounts of 0 and 569, respectively) | - | 0 | - | - |
| Other receivables (including related party amounts of 61 and (11), respectively) | -67 | -12 | 49 | -116 |
| Prepaid expenses and other current assets | -2,633 | -1,886 | -194 | 3,614 |
| Other long-term assets | - | 40 | 380 | -229 |
| Accounts payable (including related party amounts of 0 and (270), respectively) | 1,812 | -150 | -442 | -168 |
| Accrued expenses (including related party amounts of and (632), respectively) | -4,003 | 2,365 | 1,119 | -1,481 |
| Operating lease right-of-use asset and lease liabilities, net | -3 | 9 | -51 | 21 |
| Net cash used in operating activities | -20,950 | -14,726 | -19,201 | -42,824 |
| Purchases of property and equipment | 242 | 421 | 600 | 1,566 |
| Purchases of investments | 6,442 | 7,539 | 12,745 | 24,591 |
| Maturities of investments | 22,000 | 24,000 | 29,623 | 57,250 |
| Net cash provided by investing activities | 15,316 | 16,040 | 16,278 | 31,093 |
| Proceeds from issuance of common stock, net of commissions | - | 0 | - | - |
| Proceeds from exercise of stock options | - | 0 | 0 | 138 |
| Proceeds from purchase of espp shares | -131 | 0 | -99 | -134 |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | 210 | 87 | 104 | 39 |
| Payments on finance leases | 33 | 34 | 32 | 66 |
| Cash paid in connection with ipo offering costs | - | 0 | - | - |
| Net cash (used in) provided by financing activities | -112 | -121 | -37 | 167 |
| Net decrease in cash, cash equivalents and restricted cash | -5,746 | 1,193 | -2,960 | -11,564 |
| Cash, cash equivalents and restricted cash at beginning of period | 27,162 | 25,969 | 40,493 | - |
| Cash, cash equivalents and restricted cash at end of period | 21,416 | 27,162 | 25,969 | - |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)